Novartis Afinitor
Novartis' Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can no longer afford, Pharmafile has learned.

The drug is currently included in the CDF list for HR+, HER2- metastatic breast cancer (where it was NICE-rejected last year), first or second line pancreatic neuroendocrine tumours (PNET), and second line advanced renal carcinoma.

But following NHS England’s decision to re-evaluate the drugs included in the list, Pharmafile has learned that the drug will be removed for all three indications, in a move a source described as ‘devastating for patients’ diagnosed with these cancers.